Equities

Faron Pharmaceuticals Oy

FARN:LSE

Faron Pharmaceuticals Oy

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)142.50
  • Today's Change0.00 / 0.00%
  • Shares traded17.54k
  • 1 Year change-35.27%
  • Beta-0.0354
Data delayed at least 20 minutes, as of Nov 22 2024 14:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The company has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The Company's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. It is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-26.30m
  • Incorporated2006
  • Employees34.00
  • Location
    Faron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
  • Phone+358 24695151Fax+358 24695152
  • Websitehttps://www.faron.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Sareum Holdings Plc0.00-3.42m32.43m5.0032.43m5.00
Skinbiotherapeutics PLC161.65k-2.88m36.26m11.0036.26m11.00
Poolbeg Pharma PLC0.00-4.38m38.00m8.0038.00m8.00
Futura Medical PLC8.40m-3.75m100.75m12.00100.75m12.00
Scancell Holdings Plc0.00-5.86m134.79m61.00134.79m61.00
Faron Pharmaceuticals Oy0.00-26.30m148.85m34.00148.85m34.00
hVIVO PLC64.38m17.45m155.81m274.00155.81m274.00
4Basebio PLC596.00k-9.84m166.54m--166.54m--
Avacta Group Plc22.62m-25.89m171.73m154.00171.73m154.00
Bioventix PLC13.61m8.10m193.65m17.00193.65m17.00
Allergy Therapeutics plc55.20m-40.22m247.85m635.00247.85m635.00
Data as of Nov 22 2024. Currency figures normalised to Faron Pharmaceuticals Oy's reporting currency: UK Pound GBX

Institutional shareholders

12.60%Per cent of shares held by top holders
HolderShares% Held
Keskin�inen Ty�el�kevakuutusyhti� Varmaas of 24 Jun 20244.60m4.40%
Fj�rde AP-fondenas of 24 Jun 20243.59m3.43%
OP Asset Management Ltd.as of 30 Jun 20242.68m2.56%
Sp-Fund Management Co. Ltd.as of 31 Oct 20241.03m0.98%
Danske Bank A/S (Investment Management Finland)as of 31 May 2024431.72k0.41%
Fondita Fund Management Co. Ltd.as of 31 May 2024330.49k0.32%
Canaccord Genuity Wealth Ltd.as of 31 Mar 2024162.18k0.16%
Veikko Laine Oyas of 31 May 2024148.00k0.14%
Aktia Varainhoito Oyas of 31 Oct 2021117.37k0.11%
Janus Henderson Investors UK Ltd.as of 30 Sep 2024100.00k0.10%
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.